Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Blood|December 23, 1999
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host diseaseD Przepiorka, N A Kernan, C Ippoliti, et al.
Cancer Research|December 1, 1995
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemiasJ G Jurcic, P C Caron, T K Nikula, et al.
Bone Marrow Transplantation|July 1, 1997
Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutisG Michel, F Boulad, T N Small, et al.
Bone Marrow Transplantation|September 4, 2003
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemiasJ M Burke, P C Caron, E B Papadopoulos, et al.
Bone Marrow Transplantation|July 10, 2007
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host diseaseM-A Perales, N Ishill, W A Lomazow, et al.
Blood|January 13, 1999
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusionsT N Small, E B Papadopoulos, F Boulad, et al.
Bone Marrow Transplantation|January 27, 2015
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allograftsG S Hobbs, A Hamdi, P D Hilden, et al.
Blood|February 3, 1998
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host diseaseE B Papadopoulos, M H Carabasi, H Castro-Malaspina, et al.
Bone Marrow Transplantation|October 10, 2017
Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysisC Cho, M Hsu, P Barba, et al.
Bone Marrow Transplantation|January 12, 2010
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCTM-A Perales, R Jenq, J D Goldberg, et al.
Pageof 3